London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here


Come to London

video-icon

WATCH to find out why


Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Comparative study of changes in osmolarity in graft versus host disease

Poster Details

First Author: A.Hervás Ontiveros SPAIN

Co Author(s):    A. Hervas Ontiveros   P. Udaondo   A. Cisneros Lanuza        

Abstract Details

Purpose:

Our study attempts to estimate the osmolarity of the ocular surface in patients with GVHD and show the possible difference in the evolution of the osmolarity using a hypoosmolar tear (Lubristil®) versus non hypoosmolar (Artific®).

Setting:

The study was done at Universitary Hospital La Fe, Spain.

Methods:

17 patients diagnosed of GVHD underwent a Schirmer test, a study of tear osmolarity (TearLab, Equipsa) and a study of tear meniscus OCT(Cirrus). Standardized treatment was prescribed by a drop 6 times at dayday in both eyes with Lubristil® in 9 patients and one drop three times at dayday in 8 patients with Artific®.

Results:

The osmolarity values confirmed that 5% of patients had values between 340 and 360 mOsm / L, 30% obtained values between 320 and 340 mOsm / L, 50% obtained values between 308 and 320 mOsm / L and 15% had lower values of 308 mOsml / l. In the group of 9 patients treated with Lubristil®, osmolarity decreased by 65% of cases, Schirmer test improved in 75% of cases. The tear meniscus measured by OCT increased in 80% of cases.

Conclusions:

We consider the measurement of tear osmolarity by TearLab system in patients with GVHD a reliable and objective measure that allows us to establish a severity classification (mild, moderate, severe) and monitor response to treatment with artificial tears. The use of Lubristil® and Artific® has proven effective in treatment of dry eye in patients with GVHD producing a greater decrease in osmolality using Lubristil®.

Financial Disclosure:

NONE

Back to Poster listing